Adrien Tassou's Avatar

Adrien Tassou

@adrtas.bsky.social

Pain neuroscientist

25 Followers  |  35 Following  |  5 Posts  |  Joined: 03.12.2024  |  1.4465

Latest posts by adrtas.bsky.social on Bluesky


Thank you Maxime!!

09.08.2025 12:29 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

Thank you @NINDS_NIH for putting your trust in this project.

Special thanks to GrΓ©gory Scherrer for his invaluable mentoring throughout the journey!

I'll be hitting the job market soon.

Stay tuned!

08.08.2025 16:51 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

Big news! My K99 application has been awarded πŸ₯³πŸŽ‰

I'm excited to work together with @zenbrainest.bsky.social and @MarkZylka to explore how distinct peripheral neuron types shape pain representation in the brain.

08.08.2025 16:51 β€” πŸ‘ 4    πŸ” 0    πŸ’¬ 1    πŸ“Œ 1

Understanding how acute pain transitions to chronic pain after surgery is crucial, and we hope this review provides valuable insights into this complex process!

09.02.2025 14:22 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
Mechanisms of chronic postsurgical pain Chronic pain after surgery, also known as chronic postsurgical pain (CPSP), is recognized as a significant public health issue with serious medical and economic consequences. Current research on CPSP ...

🌟 Excited to share our new review published in RAPM ! 🌟

Happy to have worked with Cyril Rivat and Philippe RichebΓ© on this piece of work in which we explore the mechanisms underlying chronic post-surgical pain.

rapm.bmj.com/content/50/2...

09.02.2025 14:21 β€” πŸ‘ 3    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0
Preview
FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain The FDA approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain in adults.

A big day for pain care, and for pain science. www.fda.gov/news-events/...

30.01.2025 23:36 β€” πŸ‘ 34    πŸ” 16    πŸ’¬ 0    πŸ“Œ 1
Preview
Structure-guided design of a peripherally restricted chemogenetic system Kang etΒ al. present HCAD, a peripherally restricted DREADD based on HCA2, with a chemical actuator that avoids crossing the blood-brain barrier and selectively reduces pain in mice. This system will enable the study of peripheral physiology without affecting the central nervous system.

I am glad to share our recent work, now published in Cell! A @zenbrainest.bsky.social and Scherrer lab collaboration developing and validating a new peripherally restricted DREADD system! Great team work with Hye Jin Kang, Brian Krumm, @adrtas.bsky.social, and others
www.cell.com/cell/abstrac...

07.12.2024 01:41 β€” πŸ‘ 14    πŸ” 6    πŸ’¬ 0    πŸ“Œ 0

@adrtas is following 20 prominent accounts